Full-Time

Senior – Medical Science Liaison

Hematology, Eastern US

Biogen

Biogen

5,001-10,000 employees

Develops therapies for neurological disorders

Compensation Overview

$165k - $239k/yr

+ Cash Bonus + Equity Incentive

Cleveland, OH, USA + 4 more

More locations: Remote, OR, USA | New York, NY, USA | Research Triangle, Durham, NC, USA | Baltimore, MD, USA

In Person

Residence within the Eastern half of the continental United States; willing to travel up to 60% and occasionally overnight.

PharmD, PhD, MD

Category
Biology & Biotech (1)
Required Skills
Veeva

Get referred to Biogen

See people who can refer or advise you

Requirements
  • Advanced Scientific or Clinical degree; doctoral level required. (MD, PhD, PharmD, DNP)
  • Field Medical Science Liaison (MSL) experience required.
  • Must live within the territory, which covers the Eastern half of continental United States.
  • Effective communication: Communicates concisely, confidently, and credibly; Easily understands other points of views and responds appropriately; Listens with empathy to respond to current and future needs and adjust the communication according to the audience.
  • Digital potential: Comfortable using and experimenting with technology; Embraces and optimally utilizes new tools and systems; Demonstrates a willingness and aptitude to learn if not yet well versed.
  • Accountability: Delivers reliably against goals; Motivated to perform to meet and even exceed metrics and Key Performance Indicators (KPIs). Views metrics and KPIs as a positive opportunity to communicate value to internal stakeholders.
  • Ethical: Understands rules for industry and is committed to following them for the benefit of patients.
  • Able to travel at least 60% of the time, including ability to travel overnight and occasionally on weekends.
  • Must be 18 years of age or older with valid driver’s license and an acceptable driving record. Must have authorization and ability to drive a company leased vehicle or rental.
Responsibilities
  • Be a credible medical/ scientific expert who engages with KME and HCP to increase confidence in making the best clinical decisions pertaining to disease state and Biogen’s products in the near and long term for the benefit of patient care.
  • Focus on building deep, strategic, long-term relationships with internal & external stakeholder to be viewed as a partner rather than transactional.
  • Be a “partner in the trenches”—be responsive, engage often and be a solutions-driven conduit to leaders in the medical community.
  • Engage in projects and/or initiatives aligned to US Medical strategy, objectives and tactics
  • Be highly accountable to qualitative and quantitative medical excellence performance goals, standards, and measurements. Deliver against KME engagement plans that add high value by navigating resources at the office in collaboration with field and non-field colleagues. Capture and report KME/HCP medical insights using Veeva with the highest level of consistency and accuracy to help inform the medical and clinical strategies.
Desired Qualifications
  • Clinical experience and subject matter expertise in the respective therapeutic area is optimal.
  • Subject matter expertise in hematology, with a particular focus on paroxysmal nocturnal hemoglobinuria (PNH) and complement mediated diseases is highly preferred.

Biogen is a global biotechnology company focused on neuroscience. It discovers, develops, and delivers therapies for neurological disorders, such as multiple sclerosis and other neurodegenerative diseases. Its product process starts with research and development to identify potential drugs, followed by clinical testing and regulatory approval, ultimately leading to commercialization and patient treatment. Biogen differentiates itself through a long history (founded in 1978), a deep specialization in neuroscience, and an integrated pipeline that moves ideas from discovery to approved medicines, aiming to create value for shareholders while helping communities. The company’s goal is to advance therapies for neurological diseases to improve patients’ lives and generate sustainable value for stakeholders.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Cambridge, Massachusetts

Founded

1978

Get referred to Biogen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue reached $2.74 billion, up 3%, beating estimates.
  • LEQEMBI global sales hit $184 million; U.S. sales reached $97 million.
  • RayThera closes in Q3 2026, adding immunology pipeline depth.

What critics are saying

  • Italy's AGCM opened a Biogen antitrust probe on 2026-05-19.
  • Sandoz's Tyruko undercuts Tysabri by 20%, pressuring Biogen's MS pricing.
  • Diranersen missed its primary endpoint, so Phase 3 can still fail.

What makes Biogen unique

  • Biogen and Eisai won FDA approval for LEQEMBI IQLIK on 2026-07-28.
  • Biogen's growth portfolio topped its multiple sclerosis franchise in Q2 2026.
  • Diranersen showed 50-65% CSF tau reduction at AAIC 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

-11%

1 year growth

-11%

2 year growth

-11%
The Healthcare Technology Report
Aug 11th, 2026
Formation Bio names Michael Ehlers Chief Scientific Officer and Head of R&D.

Formation Bio names Michael Ehlers Chief Scientific Officer and Head of R&D. Published. August 11, 2026 Formation Bio has appointed Michael D. Ehlers, MD, PhD, as Chief Scientific Officer and Head of Research and Development. He will lead the AI-focused pharmaceutical company's scientific and clinical strategy across its drug portfolio. Ehlers will oversee portfolio selection and advancement from translational research through clinical development. He will also guide the scientific direction of Formation Bio's proprietary AI platform. Ehlers joins from MPM BioImpact, where he served as entrepreneur partner. He previously founded four biotechnology companies as partner and chief scientific officer at Apple Tree Partners. Three have advanced to the clinical stage, including Ascidian Therapeutics, which Ehlers led as founding chief executive officer. Earlier, Ehlers served as executive vice president of research and development at Biogen. At Pfizer, he was group senior vice president of biotherapeutics research and chief scientific officer for neuroscience. Programs advanced under his leadership have produced six approved drugs spanning five indications and four therapeutic modalities. More than 40 additional programs have entered clinical trials. "Mike has operated at this intersection his entire career, and he's going to be central to how we pick, design, and progress programs," said Formation Bio Co-Founder and CEO Benjamine Liu. Before entering the biotechnology industry, Ehlers was a neurobiology professor and Howard Hughes Medical Institute investigator at Duke University Medical Center. He holds a bachelor's degree in chemistry from Caltech and medical and doctoral degrees from Johns Hopkins School of Medicine.

The Pharma Letter
Aug 8th, 2026
Biocon announces commercial launch of Yesafili in USA.

Biocon announces commercial launch of Yesafili in USA. 7 August 2026 India's Biocon (BSE: 5325) has announced the commercial launch of Yesafili (aflibercept-jbvf) in the USA. Yesafili, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product Eylea (aflibercept) 2-mg, originated by US biotech Regeneron (Nasdaq: REGN) and licensed to Germany's Bayer (BAYN: DE). The product was approved previously and granted interchangeable designation by the US Food and Drug Administration (FDA) in May 2024, allowing substitution at the pharmacy level in accordance with state laws. However, Biogen only reached an agreement with Regeneron to launch the biosimilar in the second half of 2026. This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here. Try before you buy Free. 7 day trial access * All the news that moves the needle in pharma and biotech * Exclusive features, podcasts, interviews, data analyses and commentary from its global network of life sciences reporters. * Receive The Pharma Letter daily news bulletin, free forever. Become a subscriber £820. Or £77 per month * Unfettered access to industry-leading news, commentary and analysis in pharma and biotech. * Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results. * Daily roundup of key events in pharma and biotech. * Monthly in-depth briefings on Boardroom appointments and M&A news. * Choose from a cost-effective annual package or a flexible monthly subscription The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It's part of the key information for keeping me informed Chairman, Sanofi Aventis UK More on this story... 21 May 2024 24 October 2024 17 April 2025 Companies featured in this story. Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news Today's issue. 7 August 2026 Company spotlight. A San Carlos, California-based immunology biotech using nanobody-based multispecific biologics to target the IL-31 itch pathway, positioning its lead asset against the Dupixent franchise in atopic dermatitis and chronic pruritus. More features in biosimilars. 5 August 2026 31 July 2026 23 July 2026 22 July 2026

Business Insider
Aug 2nd, 2026
Stifel Nicolaus remains a Buy on Biogen (BIIB).

Stifel Nicolaus remains a Buy on Biogen (BIIB). Aug. 2, 2026, 11:05 AM Stifel Nicolaus analyst Paul Matteis maintained a Buy rating on Biogen today and set a price target of $242.00. * Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions * Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks According to TipRanks, Matteis is a 5-star analyst with an average return of 16.7% and a 52.83% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, ACADIA Pharmaceuticals, and Alkermes. In addition to Stifel Nicolaus, Biogen also received a Buy from Truist Financial's Danielle Brill in a report issued on July 31. However, on the same day, Wedbush assigned a Hold rating to Biogen (NASDAQ: BIIB). Based on Biogen's latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $2.74 billion and a net profit of $97.5 million. In comparison, last year the company earned a revenue of $2.65 billion and had a net profit of $634.8 million Read More on BIIB:

The Edge Media Group
Jul 29th, 2026
Biogen beats estimates as new medicines overtake multiple sclerosis business

Biogen beats estimates as new medicines overtake multiple sclerosis business. 29 Jul 2026, 11:33 pm Pedestrians walk past Biogen Inc headquarters in Cambridge, Massachusetts. Biogen CEO Christopher Viehbacher said in a statement, noting that sales of the company's newer medicines now exceed those of its older multiple sclerosis franchise. (July 29): Biogen Inc reported quarterly revenue and adjusted earnings that beat analysts' expectations as sales of newly acquired kidney and eye-disease drugs helped offset declining revenue from multiple sclerosis medicines. The company raised its revenue outlook for the year, saying sales are now expected to grow by a mid-single-digit percentage instead of declining by a mid-single-digit percentage as previously forecast. However, Biogen lowered its adjusted earnings guidance to reflect acquisition-related costs and milestone payments. Under chief executive officer Christopher Viehbacher, Biogen has gone on an aggressive acquisition strategy to expand beyond its historic neurology focus and come up with sources of new growth to replace the company's ageing portfolio of multiple sclerosis drugs. That has brought it into new therapeutic areas such as kidney disease and immunology. The exclusive allure of owning the shore Minor International's Anantara Desaru Coast Residences, the first beachfront branded residences in Malaysia, offer fully furnished villas with stunning sea views and access to resort facilities, blending luxury living with sustainability. Biogen has made "significant progress" repositioning the company for growth, Viehbacher said in a statement, noting that sales of the company's newer medicines now exceed those of its older multiple sclerosis franchise, whose revenues continue to decline. Sales of Leqembi for Alzheimer's disease, a key drug that the company sells through a partnership with Eisai Co, grew 15% in the quarter to US$184 million (RM752.03 million), roughly in line with analyst expectations. Biogen's solid results were "driven by a good quarter across the majority of its key growth products," RBC Capital Markets analyst Brian Abrahams said in a note to clients. Biogen shares rose 4.7% at 9.40am in New York. The shares had increased 17% this year through the close of trading on Tuesday, outpacing the S&P 500 Index. In May, the company closed its US$5.6 billion acquisition of Apellis Pharmaceuticals Inc, whose portfolio includes Syfovre for an immune disorder that causes blindness and Empaveli for a rare blood disorder and certain rare kidney diseases. The two medications brought in almost US$128 million in revenue to Biogen during the remainder of the quarter, the company said. Biogen lowered its adjusted earnings forecast for the year to US$12 to US$13 a share from US$14.25 to US$15.25, reflecting expected charges for acquired research and development, milestone payments and financing costs related to the Apellis deal. Excluding those items, the company's underlying earnings outlook would have increased by 60 cents a share, Biogen said. Biogen announced in June that it would acquire RayThera Inc, a closely held developer of immunology drugs, for as much as US$1 billion. Several other newer medicines also posted strong quarterly growth. Sales of Zurzuvae, a treatment for postpartum depression, jumped 53% to US$71 million, while Skyclarys, for the rare disease Friedreich's ataxia, climbed to about US$168 million, beating analysts' expectations. Uploaded by Felyx Teoh

Yahoo Finance
Jul 29th, 2026
Biogen beats Q2 expectations as growth portfolio reaches $1.06B, overtaking MS franchise

Biogen reported second-quarter results exceeding Wall Street expectations, with revenue rising 3% year-over-year to $2.74 billion, above the $2.47 billion consensus estimate. Adjusted earnings reached $3.60 per share, beating forecasts of $2.89. The company's Growth Portfolio generated $1.06 billion in revenue, up 24% and surpassing its multiple sclerosis franchise for the first time. Alzheimer's treatment Leqembi recorded $184 million in global sales, whilst Skyclarys revenue jumped 29% to $168 million and Zurzuvae climbed 53% to $71 million. Biogen raised its 2026 underlying earnings guidance to $15.85–$16.85 per share, up from $15.25–$16.25 previously. The company expects full-year revenue to increase by a mid-single-digit percentage.